# data[].attributes.body
Symmetry VNS Wins EU CE Mark for Difficult-to-Treat Depression

Cici Zhou

LivaNova is the company responsible for manufacturing the vagus nerve stimulator, Symmetry, that won FDA approval in 2019.

# data[].attributes.body
Even though the stimulator obtained FDA approval in 2019, the article was published in 2020

# data[].attributes.body
Vagus nerve stimulation has been thought to help reduce symptoms of depression, anxiety, and inflammation for years.
Auricular acupuncture has been used in traditional Chinese medicine and has been shown to create positive results in treatment of depression and anxiety Liu, et. al, 2020).
Following this line of thinking, implantable vagus nerve stimulators have been developed.

# data[].attributes.headline
The Symmetry Implantable Nerve stimulator

# data[].attributes.subject
The Symmetry Implantable Nerve stimulator

# data[].attributes.body
The way the the implantable nerve stimulator works: after the stimulator is implanted, it sends a small electrical pulse to the vagus nerve. The vagus nerve connects to the area of the brain responsible for mood. The Symmetry stimulator is specifically indicated and designed to treat severe chronic depression in patients over the age of 18 (Zhou, 2020)

# data[].attributes.attachment_link.title
New Difficult to Treat Depression Approach | LivaNova US

# data[].attributes.attachment_link.description
For people with Difficult to Treat Depression – who haven’t gotten relief from traditional treatments – vagus nerve stimulation is another way forward.

# data[].attributes.body
-It has been determined effective adjunct therapy to long term psychotherapy and psychopharmaceuticals in the management of treatment resistant depression (Zhang, et.al, 2020).
-It has positive safety profile (Vlaicu & Vlaicu, 2020).
-Little to no side effects
-No residual metabolites to interact with medications

# data[].attributes.body
-Surgical implantation has risks.
-Removal of device requires surgery
-there is a potential for nerve damage
-There is a potential for an immune response against device

# data[].attributes.body
Vagus nerve stimulation is a beneficial adjunct therapy in the treatment resistant depression. An implanted vagus nerve stimulator can ensure the proper doses of stimulation and treatment compliance.

# data[].attributes.body
Treatment resistant depression is costly and debilitating with high risk of relapse (Touya, et.al., 2022). Responses to VNS have been extremely favorable in clinical trials and leave no residual metabolites to interact with medications (Vliacu & Vliacu, 2020).

# data[].attributes.attachment_link.keywords[]
Boats and boating--Equipment and supplies

# data[].attributes.body
My top strengths are: Learner, Intellection, Input, Connectedness, and Empathy
My team members I am choosing are based on the skills that I lack that I feel are necessary to advance goals of the team.
Sheila to develop a strategy.
Alice is an achiever which means she is goal oriented.
Carter is an effective communicator to convey ideas.
Chloe is competitive, which will drive the team to win.
Fernando has focus to keep the team on track.

# data[].attributes.body
Liu, C.-H., Yang, M.-H., Zhang, G.-Z., Wang, X.-X., Li, B., Li, M., Woelfer, M., Walter, M., & Wang, L. (2020). Neural networks and the anti-inflammatory effect of transcutaneous auricular     vagus nerve stimulation in depression. Journal of Neuroinflammation, 17(1), 1–11.  https://doi-org.ezproxy.uttyler.edu/10.1186/s12974-020-01732-5

Zhang, X., Qing, M.-J., Rao, Y.-H., & Guo, Y.-M. (2020). Adjunctive vagus nerve stimulation for     treatment-resistant depression: A quantitative analysis. Psychiatric Quarterly, 91(3), 669–679. https://doiorg.ezproxy.uttyler.edu/10.1007/s11126-020-09726-5

Vlaicu, A., & Bustuchina Vlaicu, M. (2020). Vagus nerve stimulation for treatment-resistant depression: is this therapy distinct from other antidepressant treatments? International     Journal of Psychiatry in Clinical Practice, 24(4), 349–356. https://doi-        org.ezproxy.uttyler.edu/10.1080/13651501.2020.1779751

Touya, M., Lawrence, D. F., Kangethe, A., Chrones, L., Evangelatos, T., & Polson, M. (2022). Incremental burden of relapse in patients with major depressive disorder: A real-world, retrospective cohort study using claims data. BMC Psychiatry, 22. https://doi-            org.ezproxy.uttyler.edu/10.1186/s12888-022-03793-7